Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian D Davis

Showing results (151-160 of 282) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1Hilary A Vaughan, Suzanne Svobodova, Duncan Macgregor, et al.
Psycho-Oncology|October 8, 2021
Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registryJonathan G Bensley, Haryana M Dhillon, Sue M Evans, et al.
Urologic Oncology|April 1, 2017
Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control studyNathan P Papa, Robert J MacInnis, Dallas R English, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
Blood|May 10, 2003
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuliMichael Jefford, Max Schnurr, Tracey Toy, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
BJU International|March 12, 2024
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancerDickon Hayne, Katherine Ong, Nicole Swarbrick, et al.
Clinical Epidemiology|June 14, 2019
Tumor size and postoperative kidney function following radical nephrectomyRobert J Ellis, Victoria M White, Damien M Bolton, et al.
Cancer Immunity|March 10, 2005
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccinationQiyuan Chen, Heather Jackson, Mark Shackleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trialIan D Davis, Ben Brady, Richard F Kefford, et al.
Pageof 29

Showing results (151-160 of 282) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1Hilary A Vaughan, Suzanne Svobodova, Duncan Macgregor, et al.
Psycho-Oncology|October 8, 2021
Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registryJonathan G Bensley, Haryana M Dhillon, Sue M Evans, et al.
Urologic Oncology|April 1, 2017
Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control studyNathan P Papa, Robert J MacInnis, Dallas R English, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
Blood|May 10, 2003
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuliMichael Jefford, Max Schnurr, Tracey Toy, et al.
European Urology Oncology|May 31, 2022
First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the LiteratureAdam B Weiner, Aisha L Siebert, Sarah E Fenton, et al.
BJU International|March 12, 2024
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancerDickon Hayne, Katherine Ong, Nicole Swarbrick, et al.
Clinical Epidemiology|June 14, 2019
Tumor size and postoperative kidney function following radical nephrectomyRobert J Ellis, Victoria M White, Damien M Bolton, et al.
Cancer Immunity|March 10, 2005
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccinationQiyuan Chen, Heather Jackson, Mark Shackleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trialIan D Davis, Ben Brady, Richard F Kefford, et al.
Pageof 29